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ABSTRACT:
Recent studies have suggested that cancer cells behave as metabolic parasites, by 
inducing oxidative stress in adjacent normal fibroblasts.  More specifically, oncogenic 
mutations in cancer cells lead to ROS production and the “secretion” of hydrogen 
peroxide species. Oxidative stress in stromal fibroblasts then induces their metabolic 
conversion into cancer-associated fibroblasts.  Such oxidative stress drives the onset 
of autophagy, mitophagy, and aerobic glycolysis in fibroblasts, resulting in the local 
production of high-energy mitochondrial fuels (such as L-lactate, ketone bodies, and 
glutamine).  These recycled nutrients are then transferred to cancer cells, where they 
are efficiently burned via oxidative mitochondrial metabolism (OXPHOS). We have 
termed this new energy-transfer mechanism “Two-Compartment Tumor Metabolism”, 
to reflect that the production and consumption of nutrients (L-lactate and other 
catabolites) is highly compartmentalized. Thus, high-energy onco-catabolites are 
produced by the tumor stroma.
Here, we used a genetic approach to stringently test this energy-transfer 
hypothesis. First, we generated hTERT-immortalized fibroblasts which were genetically 
re-programmed towards catabolic metabolism.  Metabolic re-programming towards 
glycolytic metabolism was achieved by the recombinant over-expression of MFF 
(mitochondrial fission factor). MFF over-expression results in extensive mitochondrial 
fragmentation, driving mitochondrial dysfunction. Our results directly show that MFF-
fibroblasts undergo oxidative stress, with increased ROS production, and the onset of 
autophagy and mitophagy, both catabolic processes.  Mechanistically, oxidative stress 
induces autophagy via NF-kB activation, also providing a link with inflammation. As a 
consequence MFF-fibroblasts showed intracellular ATP depletion and the extracellular 
secretion of L-lactate, a critical onco-catabolite. MFF-fibroblasts also showed signs of 
myofibroblast differentiation, with the expression of SMA and calponin.
Importantly, MFF-fibroblasts signficantly promoted early tumor growth (up 
to 6.5-fold), despite a 20% overall reduction in angiogenesis.  Thus, catabolic 
metabolism in cancer-associated fibroblasts may be a critical event during tumor 
intiation, allowing accelerated tumor growth, especially prior to the onset of neo-
angiogenesis. 
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INTRODUCTION
Until recently, the “Warburg Effect” was considered 
the main metabolic mechanism through which cancer cells 
acquire their energy, for promoting tumor progression and 
metastasis [1-3].  More specifically, this model emphasizes 
that tumor cells develop altered mitochondrial metabolism, 
resulting in inefficient aerobic respiration and a switch 
towards glycolytic metabolism, with the increased 
conversion of glucose to L-lactate[1-3]. However, 
several key studies have shown that tumor cell lines can 
maintain normal or even elevated mitochondrial function, 
suggesting that there might be another explanation for 
increased aerobic glycolysis in human tumors [4-7]. 
In particular, over the last 10 years, it has been 
recognized that the tumor microenvironment is intimately 
involved in tumor development and progression [8-11]. 
Both in vitro and in vivo studies have now provided 
convincing evidence that “activated” stromal fibroblasts, 
a.k.a., myofibroblasts, may play a critical role in initiating 
tumor recurrence, via paracrine interactions with adjacent 
tumor epithelial cells [12-19]. 
Interestingly, recent experimental evidence indicates 
that cancer-associated fibroblasts have a catabolic 
phenotype, and undergo autophagy and mitophagy, 
resulting in the onset of glycolytic metabolism, driving 
L-lactate production, and its release into the tumor 
microenvironment. [16, 20-48]. Then, L-lactate functions 
as an onco-metabolite, stimulating mitochondrial 
biogenesis and OXPHOS in adjacent cancer cells, directly 
providing energy for tumor growth [34, 43, 44].  In 
this context, stromal L-lactate serves as a high-energy 
mitochondrial “fuel” for cancer cells. We have termed 
this new model of cancer metabolism “Two-Compartment 
Tumor Metabolism”, where two opposing metabolic 
compartments co-exist, side-by-side, with stromal 
glycolysis fueling OXPHOS in cancer cells [34, 43, 44].
A key prediction of this hypothesis, also known as 
the “Reverse Warburg Effect”, is that catabolic fibroblasts 
should promote tumor growth, without any increases in 
angiogenesis [41, 42, 48].  To test this hypothesis more 
directly, we used a genetic approach to create stromal 
fibroblasts with mitochondrial dysfunction.  For this 
purpose, we stably over-expressed MFF (mitochondrial 
fission factor) in an hTERT-immortalized human fibroblast 
cell line and studied their properties. MFF is a novel 
protein identified as a component of the mitochondrial 
membrane, which is required for mitochondrial fission 
[49]. Conversely, MFF over-expression leads to 
mitochondrial fragmentation and dysfunction. 
Here, we show that MFF over-expressing fibroblasts 
undergo oxidative stress, with increased ROS production, 
and NF-kB activation, driving the onset of autophagy, 
mitophagy, and, ultimately, glycolytic metabolism. As 
a consequence of this mitochondrial dysfunction, MFF-
fibroblasts show evidence of ATP depletion, and increased 
L-lactate production, especially under conditions of 
hypoxic stress.  Most importantly, MFF over-expression 
in stromal fibroblasts is sufficient to drive the onset of 
myofibroblastic differentiation and to effectively promote 
early tumor growth, without any increases in neo-
angiogenesis. 
RESULTS
MFF over-expression in fibroblasts induces 
mitochondrial dysfunction.
Mitochondrial Fission Factor (MFF) is involved 
in the fission process normally required to maintain the 
physiologic function of mitochondria [49]. However, it 
remains unknown if MFF over-expression plays a role in 
the breast cancer tumor stroma. Thus, we stably expressed 
MFF in hTERT-immortalized human fibroblasts. Figure 
1 shows that we successfully over-expressed MFF in 
fibroblasts, and this is especially evident upon exposure 
to hypoxic stress. 
To evaluate if increased mitochondrial fission 
alters the bioenergetic state of mitochondria, we first 
evaluated mitochondrial mass by immuno-staining with 
antibodies directed against TOMM20, a mitochondrial 
outer membrane marker. Figure 2A shows that TOMM20 
immuno-staining is reduced in fibroblasts over-expressing 
MFF, relative to controls. 
Next, we used MitoTracker to assess the status of 
mitochondrial activity. Interestingly, relative to control 
cells, MFF-fibroblasts display a strong reduction in 
MitoTracker staining, both under normoxic (Figures 
2A) and hypoxic conditions (Figures 2B), indicative of 
decreased mitochondrial membrane potential. Especially 
under hypoxia, we observed a more pronounced loss 
of mitochondrial function. To independently validate 
these data, we evaluated the expression of OXPHOS 
components upon hypoxic stress. Mitochondrial 
components of complexes I, II, III, and IV were all 
dramatically reduced in fibroblasts over-expressing MFF, 
relative to empty vector controls (Figure 2C). 
An imbalance between fusion and fission can 
cause mitochondrial dysfunction, with decreased ATP 
production. Thus, we evaluated the steady-state ATP 
levels in MFF-fibroblasts and empty vector controls under 
hypoxia. Figure 3 shows that after 12 and 24 hours of 
hypoxia, MFF-fibroblasts display a 1.7-fold and a 11.5-
fold reduction, respectively, in ATP levels, indicating that 
mitochondrial dysfunction is associated with decrease 
intracellular ATP, as predicted. 
Taken together, these data demonstrate that, as 
reported in the literature, an increase in mitochondrial 
fission drives mitochondrial fragmentation associated with 
mitochondrial dysfunction, decreased membrane potential, 
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decreased oxidative phosphorylation, and reduced ATP 
levels. 
Fibroblasts over-expressing MFF display 
metabolic remodeling, with a shift towards 
glycolytic metabolism.
Decreased mitochondrial functional activity is 
associated with metabolic changes, with a shift towards 
glycolysis. Thus, we next examined the accumulation of 
L-lactate in the conditioned media of MFF-fibroblasts 
versus control fibroblasts. Figure 4A shows that under 
hypoxic conditions, MFF-fibroblasts display a 2-fold 
increase in L-lactate secretion, relative to control cells. 
Interestingly, however, in normoxia, MFF-fibroblasts 
show a 1.5-fold decrease in lactate generation, likely 
due to compensatory adaptation. Thus, MFF promotes a 
glycolytic phenotype under conditions of hypoxia that are 
usually found within tumors in vivo. 
To validate that MFF-fibroblasts are more 
glycolytic, we performed a immuno-blot analysis 
with antibodies directed against MCT4. MCT4 is the 
transporter that extrudes L-lactate from glycolytic cells. 
MCT4 is also HIF-1a target and is an hypoxia-inducible 
gene. Consistent with the results of the lactate assay, 
Figure 4B shows that during conditions of hypoxic stress, 
MCT4 expression is upregulated in MFF-fibroblasts, as 
compared to control cells. In normoxia, however, MCT4 
levels are decreased in MFF-fibroblasts, as compared to 
control cells. These results suggest that under the low 
oxygen tension conditions found in human tumors, MFF-
fibroblasts are more glycolytic and display an efflux of 
high-energy mitochondrial fuels (such as L-lactate) into 
the extracellular microenvironment.
Fibroblasts over-expressing MFF show increased 
oxidative stress and autophagy, with NFkB-
hyperactivation.
It is well known that mitochondrial dysfunction 
induces oxidative stress and that oxidative stress promotes 
autophagy, driving the removal of damaged mitochondria, 
via mitophagy. To evaluate if MFF causes increased 
oxidative stress in stromal cells, we examined the status 
of ROS production in fibroblasts carrying the Lv-105 
empty vector or MFF. ROS levels were measured by 
FACS analysis. Interestingly, MFF-fibroblasts show a 50% 
increase in ROS production, as compared to control cells 
(Figure 5A). 
Next, the activation of autophagy/mitophagy was 
analyzed on protein extracts of fibroblasts harboring 
MFF by immuno-blotting. Interestingly, MFF induces an 
autophagy/mitophagy program in fibroblasts, as judged by 
the upregulation of markers of autophagy (LC3 I, LC3II 
and cathepsin B), and mitophagy (BNIP3 and BNIP3L) 
(Figure 5B). Beclin-1 expression remains unchanged. To 
gain insights into the mechanism(s) triggering autophagy, 
we monitored the activation the NF-kB pathway by 
immuno-blotting. Figure 5C shows that MFF-fibroblasts 
display the constitutive activation of NF-kB, suggesting 
that NF-kB activation is likely one of the mechanism(s) 
driving autophagy.
To further characterize the features of MFF-
expressing fibroblasts, we investigated if MFF induces 
a myofibroblastic phenotype. Figure 6 shows that MFF-
fibroblasts display the up-regulation of two myofibroblast 
markers, namely α-SMA and calponin.
Fibroblasts over-expressing MFF promote 
tumor growth, especially in the early phases 
of tumorigenesis, without any increase in neo-
angiogenesis. 
To evaluate the effects of MFF on tumor 
development in vivo, MFF-fibroblasts or empty vector 
control fibroblasts were co-injected with MDA-MB-231 
human breast cancer cells into the flanks of nude mice. 
Interestingly, Figure 7A and Table 1 demonstrate that 
MFF over-expression in fibroblasts increases tumor 
growth rates (up to 6.5-fold), especially in the early phases 
of tumor development, suggesting that MFF can act as a 
stromal tumor promoter. 
To evaluate if the MFF-tumor promoting effects are 
dependent on increased angiogenesis, tumor xenografts 
were immunostained with antibodies against CD31, an 
endothelial cell marker. CD31 quantification indicates 
that the tumors derived from MFF fibroblasts display a 
20% decrease in vessel density, as compared to the control 
tumors, suggesting that increased angiogenesis is not the 
mechanism promoting tumor growth.
Figure 1: Generation of fibroblasts over-expressing 
MFF. Fibroblasts over-expressing MFF were generated via 
lenti-viral transduction. Empty vector (Lv) control cells were 
generated in parallel. Fibroblasts were maintained under 
conditions of normoxia or hypoxia for 6 hours. MFF protein 
expression levels were evaluated by immuno-blotting. β-actin 
was used as an equal protein loading control.
MFF
β-Actin
HypoxiaNormoxia
Fibroblasts
Lv        MFF Lv        MFF
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DISCUSSION 
Mitochondria play a critical role in all the normal 
physiological events that maintain organismal energy 
homeostasis or balance [50-54]. As a consequence, 
mitochondrial dysregulation is likely the “root cause” of 
several human disease(s), and especially epithelial cancers 
[50, 51, 55, 56]. 
A new hypothesis is that cancer is not a cell 
autonomous disease, but rather a disease of the tumor 
microenvironment [32-34, 41] [43, 44]. We have proposed 
that cancer cells “fertilize” the tumor microenvironment, 
via the secretion of hydrogen peroxide [25, 29, 57]. 
Oxidative stress in the tumor stroma then provides high-
energy recycled nutrients, via the onset of catabolic 
metabolic processes, such as autophagy, mitophagy, and 
aerobic glycolysis [32-34, 41] [43, 44]. This localized 
production of onco-catabolites (such as L-lactate, ketones, 
and glutamine) then “fuels” the expansion and metastasis 
of cancer cells, via oxidative mitochondrial metabolism, 
driving the anabolic growth of tumors [20, 23, 58-60]. 
A simple prediction of this hypothesis is that catabolic 
fibroblasts should be able to promote the growth of cancer 
Figure 2: Fibroblasts over-expressing MFF show mitochondrial dysfunction. (A) Normoxia. To determine mitochondrial mass, 
cells were immuno-stained with TOMM20, a mitochondrial membrane marker. Note that TOMM20 is significantly decreased in MFF-
fibroblasts, suggesting that MFF reduces mitochondrial mass. To determine functional mitochondrial activity, cells were independently 
labeled with MitoTracker. Note the strong reduction in mitochondrial membrane potential. Original magnification, 40X. (B) Hypoxia. 
MitoTracker staining was performed in control (Lv-105) and MFF-fibroblasts kept under hypoxia for 6 hours (0.5% O2). Note that MFF 
induces a very strong reduction in mitochondrial membrane potential, particularly upon hypoxic stress. Original magnification, 40X. (C) 
OXPHOS protein levels were evaluated by immuno-blotting after 6 hours of hypoxia. Note that MFF-fibroblasts display a strong down-
regulation of key components of complex I (20 kDa subunit), II (30 kDa subunit), III (Core-2), and IV (COX-II). β-actin was used as an 
equal protein loading control. 
Hypoxia
Lv-105 MFF
MitoTracker
B
β-Actin
OXPHOS -- Hypoxia
Complex IV
Complex II
Complex V 
Complex III 
Complex I
Lv          MFF
C
Normoxia
Lv-105 MFF
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A
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cells, independently of angiogenesis [37, 38, 61]. 
Here, we used MFF (mitochondrial fission factor) 
[49] as a genetic tool to assess the metabolic effects of a 
“pre-fertilized” microenvironment on tumor growth and 
angiogenesis.  MFF is a novel protein that plays a key 
role in regulating the overall size and, hence, the activity 
mitochondria [49]. MFF forms a tight complex with the 
GTPase, dynamin-related protein (Drp1), and activates 
the mitochondrial fission process, causing the extensive 
fragmentation of mitochondria [49]. Mitochondrial 
fission is involved in mitochondrial turn-over by 
autophagy (mitophagy) and is associated with decreased 
mitochondrial membrane potential and low levels of ATP 
[62, 63]. 
hTERT-immortalized human fibroblasts stably 
over-expressing MFF were generated using a lentiviral 
vector approach, to evaluate the potential tumor-
promoting effects of metabolic remodeling in the tumor 
microenvironment. Now, we show that MFF-driven 
mitochondrial fission in stromal fibroblasts is indeed 
sufficient to induce a catabolic cancer-associated fibroblast 
phenotype. MFF-fibroblasts showed the up-regulation of 
myofibroblast markers (SMA and calponin), as well as 
a shift towards glycolytic metabolism. MFF-fibroblasts 
underwent constitutive autophagy and mitophagy, due 
to ROS over-production and NF-kB activation, driving 
glycolytic metabolism. For example, under conditions 
of hypoxic stress, MFF fibroblasts showed a >10-fold 
reduction in steady-state ATP levels, and a 2-fold increase 
in L-lactate secretion. Thus, increased mitochondrial 
fission is sufficient to induce oxidative stress in the tumor 
microenvironment and defects in oxidative mitochondrial 
metabolism (OXPHOS, as seen by immuno-blot analysis), 
thereby promoting a catabolic phenotype, which results 
in the over-production of the onco-metabolite, L-lactate.  
As a consequence of oxidative stress and a shift 
towards glycolytic metabolism, MCT4 was specifically 
up-regulated by hypoxia in MFF-fibroblasts.  Consistent 
with our current hypothesis, MCT4 is a HIF1 target 
gene that functions in the export of L-lactate from cells 
undergoing oxidative stress induced glycolysis, to prevent 
the intracellular accumulation of L-lactate.  Interestingly, 
we have recently shown that the up-regulation of stromal 
MCT4 in cancer-associated fibroblasts is a strong 
predictor of poor clinical outcome and lethality in human 
breast cancer patients [45, 46, 48, 64].  Conversely, the 
expression levels of MCT4 in epithelial cancer cells had 
no prognostic value, indicating that the conventional 
Warburg effect does not predict clinical outcome [45, 46, 
48]. 
In accordance with our observations on the 
prognostic value of stromal MCT4, it has been known 
for many years that elevated serum and tumor-associated 
L-lactate levels are strong predictors of poor clinical 
outcome (extensively reviewed in [46]). However, 
L-lactate production was previously attributed to increased 
glycolysis in human cancer cells, rather than in cancer-
associated fibroblasts [1]. 
Consistent with the idea that stromal L-lactate 
production is associated with lethal cancer metabolism, 
MFF-fibroblasts significantly promoted tumor growth, 
especially in the early phase of tumorigenesis (~6.5-fold), 
Figure 3: Fibroblasts over-expressing MFF show decreased ATP levels. Intracellular ATP content was measured using empty 
vector control (Lv-105) and MFF-fibroblasts maintained under normoxia or hypoxic stress (for 12 and 24 hours). Note that as compared 
to control cells, MFF-fibroblasts display a 1.7-fold and a 11.5-fold reduction in steady-statet ATP leves, respectively, after 12 and 24 hours 
of hypoxia. These results suggest that the mitochondrial dysfunction in MFF over-expressing fibroblasts is associated dramatic decreases 
in intracellular ATP.
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without any increases in tumor angiogenesis.  Rather, 
tumors grown with MFF-fibroblasts showed a 20% 
reduction in tumor vascularization, but increased tumor 
growth. Thus, stromal L-lactate production can drive 
anabolic tumor growth, as L-lactate functions as both as 
a i) high-energy mitochondrial fuel, and as a ii) signaling 
molecule that promotes mitochondrial biogenesis, in 
human cancer cells [33].  
In fact, human breast cancer cells (MCF7 cells, 
treated with and without L-lactate) were previously used 
to generate an L-lactate associated gene signature [33]. 
Importantly, breast cancer patients with this L-lactate-
induced gene signature showed an increased risk for 
recurrence, metastasis, and poor clinical outcome [33]. 
Thus, when cancer cells use L-lactate as a mitochondrial 
fuel source, this metabolic phenotype is a predictor of 
lethal cancer metabolism [33]. 
In conclusion, MFF-fibroblasts represent a new 
model system for studying the role of mitochondrial 
dysfunction and stromal L-lactate production in tumor 
initiation, progression, and metastasis, independently of 
tumor angiogenesis.  This phenotype was most evident 
under hypoxic conditions, which is consistent with the 
angiogenesis-independent nature of our findings.  
MATERIALS AND METHODS
Cell culture.
MDA-MB-231 human breast cancer cells (stably 
transfected with GFP were a gift from Dr. Fatatis’s 
Laboratory, Drexel University, Philadelphia, PA) and 
human immortalized fibroblasts (hTERT-BJ1) were 
maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) implemented with 10% fetal bovine serum 
(FBS), 100 units/mL penicillin, and 100 µg/mL 
streptomycin, at 37°C in 5%CO2. incubator.  For hypoxia 
experiments, the cells were maintained at 37°C with 
0.5%O2.
Lentiviral transduction.
For lentiviral transduction, vectors (from 
GeneCopoeia, Inc.) encoding MFF (EX-Z4766-Lv-105) or 
empty vector control (EX-NEG-Lv-105) were transfected 
into the 293Ta packaging cells, using the Lenti-Pac 
HIV Expression Packaging Kit (GeneCopoeia, Inc.), 
following the manufacturer’s instructions. Two days post-
transfection, viral supernatants were collected, centrifuged 
and filtered (0.45 µM Polyethersulfone low protein filter) 
and added to the target cells (hTERT-BJ1 fibroblasts) in 
the presence of 5 µg/ml polybrene. HTERT-fibroblasts 
were then selected with 1.5 µg/ml puromycin.
Immunoblot analysis.
Cells were harvested into lysis buffer (10mM 
Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 
60mM octylglucoside), supplemented with protease and 
phosphatase inhibitors (Roche Applied Science). After 
rotation at 4°C for 40 minutes, samples were centrifuged 
10 min at 13,000x g at 4°C and the supernatants were 
collected to remove insoluble debris. For NF-kB 
detection, cells were scraped in RIPA lysis buffer (50 
mM Hepes, 2 mM EDTA, 0.1% SDS, 50 mM NaCl, 1% 
NP40), containing protease and phosphatase inhibitors, 
sonicated and incubated on ice for 10 minutes. Then, 
samples were centrifuged 10 min at 13,000x g at 4°C 
and the supernatants were collected. Protein samples 
were separated by SDS-PAGE, and transferred to a 
nitrocellulose membrane. Membranes were blocked 
with TBS-Tween (20 mM Tris pH 7.6, 150 mM NaCl, 
and 0.05% Tween-20) supplemented with 1% BSA and 
Figure 4: Fibroblasts over-expressing MFF show 
increased L-lactate generation and MCT4 expression, 
under hypoxia. (A) Empty vector (Lv-105) and MFF-
fibroblasts were grown under normoxic or hypoxic conditions (6 
hours), and then subjected to biochemical analysis, to determine 
L-lactate content in the tissue culture media. The graph shows 
that MFF-fibroblasts show a 1.5-fold decrease in L-lactate 
production under normoxia. However, when challenged with 
hypoxia, MFF-fibroblasts exhibit a 2-fold increase in L-Lactate 
generation, as compared with empty vector (Lv-105) control 
cells. (B) MCT4 is a transporter which mediates the efflux 
of L-lactate and is a marker of oxidative stress and aerobic 
glycolysis. Empty vector and MFF-fibroblasts were maintained 
under normoxia or hypoxia (6 hours), and were subjected to 
immuno-blotting with anti-MCT4 antibodies. Consistent with 
the L-lactate assay results, MCT4 levels are down-regulated in 
MFF-fibroblasts under normoxia; in contrast, MCT4 levels are 
strongly up-regulated in MFF-fibroblasts under hypoxia. 
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4% nonfat dry milk for 1 hour at room temperature. For 
phospho-antibodies, the blocking solution contained only 
5% BSA in TBS-Tween. The membranes were incubated 
with primary antibodies for 1 hour at room temperature. 
The following antibodies were used: MFF (Abcam, 
ab81127); MCT4 (Sigma-Aldrich, SAB4503555); Smooth 
Muscle Actin (Dako, M0851); Calponin 1/2/3 (FL-297) 
(Santa Cruz, sc-28545); BNIP3 (Abcam, ab10433); 
BNIP3L (Abcam, ab8399); Cathepsin B (FL-339) 
(Santa Cruz, sc-13985); LC3 (Abcam, ab48395); NF-kB 
p65 (Cell Signaling, 3034); phospho-NF-kB p65 (Cell 
Signaling, 3037); Mitoprofile total OXPHOS cocktail 
(Mitosciences, MS601). Then, blotting membranes were 
washed, incubated for 30 min at room temperature with 
horseradish peroxidase-conjugated secondary antibodies 
(anti-mouse, 1:6.000 dilution (Pierce) or anti-rabbit 
1:5.000 (BD Biosciences/Pharmingen). HRP activity 
was visualized by enhanced chemiluminescent substrate 
(Thermo Scientific). As internal control, all membranes 
were subsequently stripped (Restore Western Blot 
Stripping Solution, Thermo Scientific) and re-probed with 
anti β-actin antibodies (Sigma-Aldrich, A5441).
Mitochondrial activity.
Fibroblasts were seeded onto glass coverslips in 
12-well plates in complete media. After 24 hours, the 
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Figure 5: Fibroblasts over-expressing MFF show increased ROS generation, and induction of autophagy, with NF-kB 
hyper-activation. (A) ROS levels were measured by FACS analysis, as described under Materials and Methods. Note that MFF over-
expression induces a 50%  increase in ROS production, as compared to control cells. (B) Induction of an autophagic/mitophagic process 
was analyzed on cellular extracts of fibroblasts expressing MFF and empty vector controls by immunoblotting. Note that MFF-fibroblasts 
show the up-regulation of several markers of autophagy (LC3I/II and cathepsin B), and mitophagy (BNIP3 and BNIP3L), as compared to 
control cells. No changes were observed for Beclin-1 expression. β-actin is shown as an equal loading control. (C) NF-kB activation was 
monitored by immuno-blotting with phospho-NF-kB antibodies. Note that MFF-fibroblasts show constitutive NF-kB activation, relative 
to control cells, suggesting that NF-kB activation maybe the mechanism driving the induction of autophagy. β-actin was used as an equal 
protein loading control.
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media was changed to DMEM containing 2% FBS. After 
72 hours, cells were incubated with the pre-warmed 25 
nM MitoTracker staining solution (CMTMRos, M7510, 
Invitrogen) for 15 minutes, and washed (3X) in PBS 
supplemented with calcium and magnesium. Then, cells 
were fixed with 2% PFA, washed and incubated with 
DAPI nuclear stain (Invitrogen, D3571). Samples were 
mounted with Prolong Gold Anti-Fade mounting reagent 
(Invitrogen, P36930). Images were collected with a Zeiss 
LSM510 meta confocal system and acquired with a 60X 
oil objective.
Immuno-fluorescence.
Cells were washed three times in PBS with 0.1 mM 
CaCl2 and 1 mM MgCl2 and fixed with 2% PFA. Then, 
the cells were permeabilized with ice cold methanol for 
10 min, incubated with 25 mM NH4Cl in PBS for 10 min, 
washed with PBS, and incubated with primary antibodies 
(TOMM20, Santa Cruz, sc-17764) for 1 hour a room 
temperature. Then, cells were washed with IF buffer 
(PBS, 1% BSA, 0.1% Tween 20), and incubated for 30 
min with fluorochrome-conjugated secondary antibodies. 
Finally, slides were incubated with the nuclear stain DAPI 
and mounted. Images were collected with a Zeiss LSM510 
meta confocal system, using a 40X oil objective. 
ROS Assay.
Fibroblasts were seeded at a density of 130,000 per 
well in 12-well plates in standard media in quadruplicate. 
ROS levels were evaluated after 48 hours. Briefly, cells 
were washed and incubated for 15 min at 37°C with 10μM 
CM-H2DCFDA (Invitrogen). Then, cells were washed 
with HBSS and placed in standard media for 15 min at 
37°C. Cells were then washed, trypsined, resuspended in 
PBS. The resulting signal was quantified by FACS using 
the BD LSRII (BD Bioscience). The results were analyzed 
using FlowJo software (Tree star Inc.).
Lactate Assay.
120,000 cells were plated into 12-well plates in 
standard media in quadruplicate. After 24 hours, the 
media was changed to DMEM containing 2% FBS. 
Two days later, the media was harvested to measure the 
concentration L-lactate using the EnzyChrom L-Lactate 
Assay Kit (BioAssay Systems, ECLC-100), according to 
the manufacturer’s instructions. For hypoxia experiments, 
cells were incubated for 6 hours in a hypoxia workstation 
(0.5% O2), before lactate measurement. Results were 
normalized to the protein content.
ATP Determination.
100,000 cells were seeded in 24-well plates in 
complete media in quadruplicate. The day after, cells were 
incubated in normoxia or in hypoxia for 12 or 24 hours. 
Then, cells were lysed in 100 µl of extraction buffer (4 
mM EDTA and 0.005% Triton X-100). ATP concentrations 
Figure 6: Fibroblasts over-expressing MFF show 
myofibroblastic features. To evaluate if MFF-fibroblasts 
acquire myofibroblastic features, cells were analyzed by 
immuno-blotting with antibodies directed against α-SMA and 
calponin. Note that MFF-fibroblasts show increased expression 
of two myo-fibroblast markers, namely α-SMA and calponin, 
indicating that MFF promotes a myofibroblastic differentiation. 
β-actin was used as an equal protein loading control. 
β-Actin
SMA
Calponin
Lv       MFF
Table 1: MFF over-expressing fibroblasts increase tumor growth, especially 
during the early phase of tumorigenesis. Note that fibroblasts over-expressing 
MFF greatly increase tumor growth. Fold increases in tumor growth rates for 
MDA-MB-231 xenografts are shown (co-injected with MFF over-expressing 
fibroblasts versus empty vector controls (Lv-105)). Interestingly, the role of 
MFF is most relevant in the early phase of tumor development, suggesting that 
increased mitochondrial fission in the stroma can metabolically promote and 
support tumor initiation.
Days
Post-Injection
Lv-105
Tumor 
Volume
MFF Tumor 
Volume
Fold-
Increase
(MFF/control)
p-values
14 8.51 55.37 6.5 0.003
17 48.14 112.42 2.3 0.01
21 80.40 152.32 1.9 0.047
24 94.38 238.42 2.5 0.009
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were determined by using the ATP determination kit 
(Invitrogen, A22066). Luminescence was read using 
a luminometer (Biotek Synergy HT), and values were 
calculated based on an ATP standard curve. Results were 
normalized to the protein content.
Animal Studies.
All animals were housed and maintained in a 
barrier facility at the Kimmel Cancer Center at Thomas 
Jefferson University under National Institutes of Health 
(NIH) guidelines. Mice were kept on a 12-hour light/dark 
cycle with ad libitum access to food and water. Studies 
were approved by the Institutional Animal Care and Use 
Committee (IACUC) of Thomas Jefferson University. 
Briefly, MDA-MB-231 cancer cells (1 x 106) admixed with 
transfected fibroblasts (3 x 105) in 100 µl of sterile PBS, 
were injected into the flanks of athymic NCr nude mice 
(NCRNU; Taconic Farms; 6–8 weeks of age). Mice were 
then sacrificed at 3-4-weeks post-injection; tumors were 
dissected and fixed with 10% formalin or flash-frozen in 
liquid nitrogen-cooled isopentane.
CD31 immuno-histochemistry.
Seven micron frozen sections were cut and fixed 
with 4% paraformaldehyde in PBS for 10 min at 4oC, and 
washed 3X with PBS. The sections were blocked with 
10% rabbit serum and incubated overnight at 4oC with rat 
monoclonal CD31 antibodies (550274, BD Biosciences, 
San Jose, CA) at a dilution of 1:200. The sections were 
then washed and subsequently incubated with biotinylated 
rabbit anti-rat IgG (Vector Labs, Burlingame, CA), 
and then with streptavidin-HRP (Dako, Carpinteria, 
CA). Immunoreactivity was revealed with 3, 3’ 
diaminobenzidine and sections were then counter-stained 
with hematoxylin (Vector), dehydrated and mounted. 
Quantification of CD31(+) Vessels.
Four tumors were randomly selected from each 
group and sections were prepared and stained with a CD31 
antibody, as described [22, 23]. For each tumor, 8-16 
representative fields (0.25 mm2 per field) were selected 
and the numbers of CD31-positive vessels were quantified 
using an ocular micrometer and a 20x objective lens. 
Only healthy, non-necrotic tumor areas were evaluated. 
The numbers of vessels per field were averaged and the 
overall average per group and standard deviation were 
calculated. Statistical significance was evaluated using the 
Student’s t-test. p-values lower than 0.05 were considered 
statistically significant.
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